Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2578 vs darbepoetin alfa in ESA-naive non-dialysis CKD anemia (Phase IIb)
2009-013286-26Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Mar 2010
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of MK2578 in anemia of renal disease (2 arms), sponsored by Merck & Co. Primary endpoint: Change from baseline hemoglobin at Week 4. Started Mar 2010; status: terminated.
02
Drugs
MK2578
03
Conditions
anemia of renal disease
Beyond the preview
Go deeper on 2009-013286-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013286-26.